Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

By sjmartinez • November 6, 2022

Gong J, Thomassian S, Kim S, Gresham G, Moshayedi N, Ye JY, Yang JC, Jacobs JP, Lo S, Nissen N, Gaddam S, Tighiouart M, Osipov A, Hendifar A. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Nov 4;12(1):18731. doi: 10.1038/s41598-022-23619-6. Erratum for: Sci Rep. 2022 Sep 2;12(1):15013. PMID: 36333397; PMCID: PMC9636406.

Tags: General Internal Medicine, Publications

Broad repetitive transcranial magnetic stimulation (rTMS) of the precuneus in Alzheimer’s disease: A rationale and study design

Leuchter MK, Oughli HA, Durbin KA, Jackson NJ, Elashoff D, Chang TS, Corlier J, Ngo D, Matthews C, Wong D, Fogel BL, Bitan G, Leuchter[...]

An Urgent Need to Improve Accessibility of Preventive Services for People With Disabilities

Hotez E, Duan S, Ma J, Shankar S. An Urgent Need to Improve Accessibility of Preventive Services for People With Disabilities. Ann Intern Med. 2025[...]

COVID-19 Pandemic and the Developmental Health of Kindergarteners

Perrigo JL, Morales J, Jackson N, Janus M, Stanley L, Wong M, Halfon N. COVID-19 Pandemic and the Developmental Health of Kindergarteners. JAMA Pediatr. 2025[...]